The Prevalence and Prognostic Relevance of ABO/Rh Blood Groups in Metastatic Breast Cancer Patients Undergoing Cyclin-Dependent Kinase 4/6 Inhibitors Therapy.
| Autor: | Akdag, Goncagul, Dogan, Akif, Yildirim, Sedat, Kinikoglu, Oguzcan, Kudu, Emre, Surmeli, Heves, Isik, Deniz, Sever, Ozlem Nuray, Odabas, Hatice, Yildirim, Mahmut Emre, Turan, Nedim |
|---|---|
| Předmět: |
BREAST cancer prognosis
BREAST tumors TREATMENT effectiveness RETROSPECTIVE studies DESCRIPTIVE statistics CHI-squared test METASTASIS KAPLAN-Meier estimator RH factor MEDICAL records ACQUISITION of data STATISTICS ABO blood group system PROGRESSION-free survival DATA analysis software CONFIDENCE intervals CYCLIN-dependent kinases DISEASE progression OVERALL survival PROPORTIONAL hazards models BLOOD CHEMICAL inhibitors |
| Zdroj: | Eurasian Journal of Medical Investigation; 2024, Vol. 8 Issue 3, p212-219, 8p |
| Abstrakt: | Objectives: Breast cancer (BC) is the most commonly malignancy in women. The emergence of cyclin-dependent kinase inhibitors (CdK 4/6i) has significantly improved prognosis. Until now, no predictive factor of response to CdK4/6i has been identified. This study investigates the relationship between ABO and Rhesus (D) groups and the therapeutic response to CdK4/6i. Methods: This retrospective study registered records of mBC treated with CdK 4/6i at the Kartal Dr. Lutfi Kirdar City Hospital. Results: The study comprised 185 metastatic BC patients. During the study period, 32 patients (17.3%) died. The median overall survival (OS) was 18.3 months. The A group had the highest number of deaths (n=16), while the B group had the highest death rate proportionally (23.0%). Interestingly, no deaths were observed in the AB group. Disease progression was observed in 84 patients (45.4%). An analysis of the average progression-free survival (PFS) showed that patients with group O was PFS of 37.8 months (95% Confidence Interval (CI): 31.0-44.6), group A was 19.7 months (95% CI: 16.6-22.8), group B was 19.6 months (95% CI: 14.3-24.8), and group AB was 14.2 months (95% CI: 28.5-36.8). No statistically significant difference was observed when an OS (p=0.23) and PFS (p=0.138) analysis was performed according to ABO groups. In the univariate analysis, the Rh factor did not serve as a prognostic factor on either PFS or OS. Conclusion: We found no prognostic effect of blood group or Rh status on overall survival and progression-free survival in patients. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|